Oxlund CS, et al. - In the randomized, controlled Systolic Blood Pressure Intervention Trial (SPRINT), 9,361 people ≥50 years of age were analyzed to study the safety and effectiveness of intensive blood pressure management and also to elaborate its impact across body mass index (BMI) measures. Though not significant after adjusting for clinical factors, they noted a significant, J-shaped correlation of BMI with the risk of all-cause mortality, stroke, and grave adverse events. They found a decline in the primary efficacy endpoint (acute coronary syndromes, stroke, heart failure, or cardiovascular death) and an increase in the primary safety endpoint (serious adverse events) due to lowering of intensive blood pressure vs standard targets, consistently across all measures of BMI. Overall, they suggested insignificant or no modification in overall efficacy and safety of intensive blood pressure lowering by baseline BMI among high-risk older adults.